Superpower peptides available for pre-order. Get first access.

Not FDA-approved

Hormones & metabolism

MOTS-c

EvidenceLimited research
ClassMitochondrial-derived peptide

MOTS-c is a mitochondrial peptide studied as an exercise mimetic. See what preclinical research shows, why human evidence is lacking, and its FDA status.

Reviewed by
William Maish, MD MBA MPH, Clinical Product Lead
Published
April 18, 2026
Last updated
October 29, 2026

Key takeaway

MOTS-c is a small peptide encoded within the mitochondria, studied as an "exercise mimetic" for metabolic health, and sold on the "research peptide" market. Its evidence is preclinical and observational, with no completed trials testing the administered peptide in people. As of October 2026 it is still not FDA-approved, but the FDA has granted enforcement discretion allowing it to be compounded by 503A pharmacies while formal rulemaking remains pending.

At a glance

FDA statusNon-FDA-approved peptide sold in the wellness/gray market
What it isNaturally occurring mitochondrial-derived peptide studied in metabolism and exercise
ResearchAnimal and observational; no completed interventional human trials of the given peptide
CompoundingCompoundable by 503A pharmacies under FDA enforcement discretion since October 28, 2026, pending formal rulemaking; still not FDA-approved
Evidence strengthLimited research

What is MOTS-c?

MOTS-c is a naturally occurring 16-amino acid peptide encoded within the mitochondria, the cell's energy structures. It has drawn research interest as a possible "exercise mimetic" for metabolic health. It is sold through wellness and "research peptide" channels, and it is not an approved medicine.

How does it work?

MOTS-c is proposed to move into the cell nucleus under metabolic stress and influence genes that regulate metabolism, including the AMPK energy-sensing pathway, improving muscle glucose handling and insulin sensitivity. Its blood levels reportedly decline with age and rise after intense exercise. In mice, MOTS-c improved exercise capacity and metabolic markers. These are cell and animal findings. This describes the proposed mechanism, separate from demonstrated benefit in people.

Is it FDA-approved?

No. MOTS-c is not approved by the FDA. In July 2026 the FDA's Pharmacy Compounding Advisory Committee gave MOTS-c a non-binding favorable vote toward the 503A compounding list. On October 28, 2026, the FDA granted enforcement discretion3 allowing 503A pharmacies to compound MOTS-c (along with five other peptides) while the formal rulemaking to add it to the 503A bulks list is still pending. This permits licensed pharmacies to compound MOTS-c, but it is not the same as FDA approval, it carries no stated end date, and it does not reflect any new finding that MOTS-c is safe or effective.

What does the research show?

The evidence is largely preclinical:

Study typeWhat it shows
Cell and rodent studiesThe source of the metabolic and exercise effects, according to PubMed, summarized in reviews1 of its therapeutic potential and of mitochondrial peptides and exercise2
Human studiesMostly observational rather than interventional, showing that circulating MOTS-c rises after exercise
Trials of administered MOTS-cNone completed for any metabolic or performance use

Its marketed benefit is therefore unproven in people.

More for hormones & metabolism

Sources: reviews of MOTS-c and mitochondrial-derived peptides (Frontiers in Endocrinology, 2023, DOI: 10.3389/fendo.2023.11205331; Biochimica et Biophysica Acta General Subjects, 2021, DOI: 10.1016/j.bbagen.2021.1300112), indexed on PubMed; and reporting on the July 2026 FDA advisory committee vote. This document is educational, is not medical advice or a health claim, and is not an offer to sell any product.